SCHEMBL23901674

SCHEMBL23901674

Cc1cc(C2CCOCC2)nc2c(C(=O)NCCc3ccc4c(c3)CCC4)ncn12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.38
ALDH1A1 P00352 1/20 0.38
TSHR P16473 1/20 0.38
HKDC1 Q2TB90 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAPK1 P28482 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
NOS1 P29475 1/20 0.35
NOS2 P35228 1/20 0.35
CA12 O43570 1/20 0.35
CA1 P00915 1/20 0.35
CA2 P00918 1/20 0.35
CA9 Q16790 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
F2 P00734 1/20 0.35
PRSS1 P07477 1/20 0.35
PRSS2 P07478 1/20 0.35
PRSS3 P35030 1/20 0.35
CNR2 P34972 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22472770 0.84 ALDH1A1 (0.42) LMNAALDH1A1HKDC1CA12CA1
SCHEMBL23901591 0.84 RAB9A (0.43) LMNAALDH1A1HSD17B10MAPK1MAPT
SCHEMBL23901677 0.83 L3MBTL1 (0.45) LMNAALDH1A1TSHRHKDC1HSD17B10
SCHEMBL22472759 0.80 CA12 (0.40) LMNAALDH1A1CA12CA1CA2
SCHEMBL23901678 0.79 LMNA (0.38) LMNAALDH1A1TSHRMAPK1F2
SCHEMBL23901684 0.75 CNR1 (0.38) LMNAALDH1A1TSHRHKDC1HSD17B10
SCHEMBL22472782 0.75 APOBEC3A (0.45) LMNAALDH1A1HSD17B10L3MBTL1CA12
SCHEMBL22472803 0.73 USP28 (0.40) LMNAALDH1A1HKDC1NOS1NOS2
SCHEMBL23901679 0.73 RAF1 (0.34) ALDH1A1HSD17B10IRAK4CNR2KMT2A
SCHEMBL23901467 0.72 IRAK4 (0.34) ALDH1A1HSD17B10MAPK1IRAK4F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2021-10-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210309661-A1 IMIDAZO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, GBA2 LMNA 836/4885ALDH1A1 1121/4885TSHR 2719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.